SBC-103

recombinant human N-acetylglucosaminidase (NAGLU) enzyme · Alexion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SBC-103, covering 2018-04-17 to 2018-07-12. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB) [Phase 1, Phase 2]

See pricing